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Bone Marrow Transplantation Supports Patients
through High-Dose Chemotherapy
Karel A. Dicke, M.D., never tires of telling stories about
patients whose lives were saved by bone marrow transplantation at The University of Texas M. D. Anderson Cancer
Center, where he is a professor of medicine and pioneered
the procedure.
There is the man who went through transplantation
because he had recurrent Hodgkin's disease. A year later he
started his own aircraft company. Today he is a pilot.
Then there is the young Netherlander, in transplantation
for the same reason, who nearly landed in the Dutch army

when he went home after recovering and finishing college
in Houston. Only the scar from his lung operation, which
provoked the army doctor to ask about the potential
recruit's medical history-and a letter from Dicke confirming that history-kept him out of the draft.
"We are here," Dicke said, "not to arrange the funeral,
but to kick the door open to more treatment. Two thingsimprovement of the survival rate and a good quality of life
for the patients-are what counts."
The bone marrow transplantation program at M. D.
Anderson, now in its fourteenth year with a record of more

than 1000 of the procedures, has become a major way of
supporting patients through high-dose chemotherapy.
The program expanded as autologous bone marrow
transplantation was offered to new categories of patients,
including those with recurrent solid tumors, and as the
rates oflong-term survival ofleukemia and lymphoma
patients rose. Autologous transplantation now far outnumbers the allogeneic procedure at M. D. Anderson
because using the patient's own marrow avoids problems
of unavailability or incompatibility of donors, who usually
have to be siblings, and the risks of graft-versus-host disease. In leukemia and lymphoma, however, autologous
bone marrow transplantation requires special care to assure
that the patient's bone marrow is clear or almost clear of
malignant cells.

Allogeneic marrow transplantation is still done for
patients with acute and
chronic leukemia when a
donor is available, for this
therapy is curative, Albert B.
Deisseroth, M.D., M. D.
Anderson professor, chair of
the Department of Hematology, and chief of the transAlbert B. Deisseroth
plantation center, explained.
But perhaps transplantation should be done earlier in the
course of the disease, he said, because nearly half of chronic
myelogenous leukemia patients with donors can be cured
by high-dose chemotherapy and bone marrow transplantation (cured meaning five years of freedom from disease) .
Unfortunately, not everyone has a donor. The first-line
continued on page 2
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treatment, interferon, controls the disease in 20% of
patients, and another 25% of those whom interferon does
not help are cured by allogeneic transplantation.
Although the risks of marrow donation itself are small,
the procedure is "tough therapy," with its own toxicity,
Deisseroth said. Patients are never far from severe viral or
fungal infections while their immunity is suppressed by
high doses of drugs, a danger that has kept arguments
about choosing high-dose chemotherapy and transplantation or treatment with conventional doses from being
resolved. "But when cure is the outcome, we must take
that chance," he said.
''We still cannot tell at the beginning of therapy who will
a~d will ~ot benefit from interferon or from transplantat10n. A big problem for us is to know whom we should or
shouldn't subject to the risk of death from the treatment's
toxicity and to know who should receive interferon. We
now have a new program at M. D. Anderson that is
desig~ed ~o fit the best therapy to each patient by using a
comb~nat1~n of autologous bone marrow transplantation
and biological therapy,'' Deisseroth said.

Long Remissions in Hodgkin's D isease
For patients with lymphoma-Hodgkin's disease and
non-Hodgkin's lymphoma-Dicke and his team are
engaged in studies with researchers at t he University of
Nebraska and in Rotterdam, the Netherlands.
Patients with Hodgkin's disease who have relapsed are
given two courses of normal-dose chemotherapy. If they
respond well to this, they may enter the high-dose program
and undergo autologous transplantation. "We predict,"
Dicke said, "that between 50% and 60% of the patients
will be free of disease for a long, long time. I can't say cured
because in Hodgkin's disease one can have a late relapse,
maybe 10 years lattr. ''
The record of bone marrow transplantation for nonHodgkin's lymphoma is different because, so far, standard
therapies have brought high complete remission rates; for
them, high-dose chemotherapy and transplantation have
not proved better.

For Solid Tumors
As it became obvious that autologous transplantation
supports many types of patients through intensive chemotherapy for blood and lymphatic-system malignancies, clinicians began about eight years ago to use the method for
patients being treated for the solid tumors of, for example,
breast cancer.
Fifty percent of breast cancer patients are cured by surgery and radiation-"good news and bad news," said
Deisseroth. "What can be done to circumvent the problem in the uncured half, in whom the disease is disseminated by the time it is diagnosed? "
Adjuvant therapy after surgery and radiation improves
survival, he said, but it does not save everybody. "Here
again, the problem is deciding who will do well with transplantation and who will not. It's important not to wait six
months when even people who will benefit from transplantation will be harder to treat.''
Some ways of assessing prognosis are known, Deisseroth
said, including bulk and distribution of disease, type of
estrogen receptors (positive being better), and the number
of oncogenes present, particularly the recently identified
neu oncogene.

Complete Remissions After Three to Six Years
Some of the M. D. Anderson physicians' experience with
leukemia tre_atment ~eems to argue for early autologous
transplantation, durmg a patient's first remission or early in
the disease course, according to Dicke. Ofl8 patients with
acute myelo~enous ~eukemia who underwent autologous
transplantat10? ~unng 1983-1985, the first group studied
her~, 10 are sttll m complete remission. The longest followup 1s 6 y_ears ~nd the briefest is 3, a dramatic change from
the median disease-free survival of approximately 16 months
after diagnosis for patients without transplantation.
These patients' marrow,
aspirated during remission, did
not need to be treated in vitro,
as is often done to destroy
malignant stem cells, Dicke
said, because ''we gave basically thorough, aggressive chemotherapy, in this case with
arabinoside and amsacrine. At
the time of transplantation
Karel A. Dicke
c
.
'
t h ere1ore,
t h e patient's
leukemic cell burden was very low.''
The process Dicke calls '' in vivo purging'' is usually done
by exposing a patient repeatedly to standard-dose chemotherapy, which destroys the leukemic cells in the marrow.
This type of therapy has low toxicity and can therefore be
done without compromising her:natopoiesis. This experi_ence, too, argues for transplantation during an earlier stage
of leukemia, when leukemic cells are more susceptible to
eradication, and for extending studies of predictive markers
like aberrant chromosomes, oncogenes, and, in the case of
breast cancer, estrogen receptors, Dicke said.

Transplantation Twice
Patients with recurrent breast cancer are offered autologous transplantation at several cancer centers-Dana Farber
Cancer Center at Harvard and Duke University Cancer
Center, among others-but only at M . D. Anderson is
the chemotherapy regimen spread over two periods, and
patients go through two transplantation procedures. These
are usually a month apart, which means patients spend at
least eight weeks in the hospital.
continued on page 7
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Osteosarcoma: Expandable Prostheses and Allografts
Reduce the Need for Amputation
"Osteosarcoma 1s. an

tion. Depending on the growth rate, you could expand the
prosthesis every six months or so to keep the leg length
equilibrated," Murray said.
The critical issue in determining whether an expandable
prosthesis is indicated is the skeletal maturity of the child.
"Females generally reach skeletal maturity between the
ages ofl3 and 15, whereas males do so a bit later, between
15 and 17," Murray said. "Consequently, at the age ofl5
children can be operated on as adults. These patients can
receive nonexpandable devices, and any problems caused by

extremely virulent tumor.
Without a multimodality
approach to treatment, survival rates would average no
more than 15% to 20%. Now,
however, with a combination
of surgery and chemotherapy,
five-year survival rates average
· about 70% for adults and chilJohn A. Murray
dren," said John A. Murray,
M. D. , chief of orthopedic services at the M. D. Anderson
Cancer Center. Murray performs two procedures, prosthesis implantation and allografting, that are important
adjuncts to therapy for osteosarcoma. These procedures
are necessary not only for eradicating local disease, but also
for limb preservation.

Indications for Prostheses
Expandable prostheses were developed about five years
ago for the surgical treatment of children with osteosarcoma. "Expandable prostheses allow us to operate on children at an earlier age," said Murray. "Nonexpandable
prostheses can't accommodate the child's growth. The
resultant discrepancy in leg length would be more of a burden than a help. In the past the only way to excise the
tumor-bearing bone was to amputate the leg. Candidates
for prostheses were limited to adults or to children who
had no more than six centimeters to grow."

Figure 1. Expandable prostheses, both folded at knee joint (left). Top, distal femur
prosthesis; bottom, proximal tibia prosthesis.

growth can, in most cases, be easily corrected postoperatively; but younger patients need expandable prostheses to
compensate for growth."
The exent and location of metastasis may affect the decision to implant an expandable prosthesis, Murray said.
''Metastases to the center of the parenchyma of the lung
are usually most easily resectable. In such cases, if the pulmonary lesion and the primary lesion respond to preoperative chemotherapy, we wouldn't hesitate in implanting the
prosthesis. In other cases, however, the metastases are in
locations in which the hazard of resection is lethal, in the
vertebrae or skull, for example. These patients generally are
not considered for an expandable prosthesis."

Like other prosthetic devices, expandable prostheses have
an articular surface and an intermedullary stem, but the
expandable devices also have a machine screw attached to
a ratchet. "The machine screw allows you to separate the
two ends. The prosthesis can then be locked in that posi-

No Diagnostic Symptoms
The diagnosis of osteosarcoma is often delayed because in
its initial stages it has no distinctive symptoms, Murray
continued on page 6
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Genetic Linkage Analysis of Familial Wilms' Tumor
by Vicki Huff, Ph.D.
Department ofBiochemistry
and Molecular Biology

Wilms' Tumor
Wilms' tumor is a pediatric renal neoplasm that affects
approximately 1 in 10,000 children. In the United States,
300 to 400 cases are seen annually. Occasionally (5% to 7%
of cases) aniridia, genitourinary anomalies, or mental retardation is also observed in Wilms' tumor patients. Tumors
develop in both kidneys in 5% to 10% of patients. Most
tumors (99%) occur sporadically, with no known affected
relative. Ofinterest for this study, however, was the 1% of
Wilms' tumor cases that are familial. In t hese cases siblings
or cousins are most often affected. Based on epidemiologic
observations of the age of onset and of the frequency of
multiple tumors in familial and nonfamilial cases, Dr. Louise
Strong, Department ofExperimental Pediatrics, along with
Dr. Alfred Knudson, who is currently with the Fox Chase
Cancer Research Institute, proposed that at least two
mutations are critical for the development of Wilms'
tumor. In most sporadic unilateral cases, a tumor arises
following two somatic mutations in the developing kidney,
whereas in familial and bilateral tumors, though the second
mutation is somatic, the initial mutation is thought to be
inherited via a germ cell.

Identifying, isolating, and
characterizing genes involved
m carcinogenesis are important approaches for understanding cancer etiology, biology, and treatment. However,
cancer is a heterogeneous disease, and for any one cancer
many genes may be involved in
the multistep process of carVicki Huff
cinogenesis. As a result, the
goal of understanding the role of genetic changes in carcinogenesis is made difficult. The study of familial cancers,
however, serves to circumvent some of these complications.
Since the early part of this century, investigators have
noted families in which individuals in multiple generations
are affected with the same type of cancer. This observation
has led investigators to believe that, though many genes
may ultimately be involved, a single (mutant) gene may be
responsible for the familial predisposition to a particular

Initial Studies Implicate Chromosome Band llpl3
in Wilms' Tumor
Cytogenetic studies of normal blood cells from Wilms'
tumor patients with aniridia revealed the location of a gene
important in Wilms' tumor. From these studies, investigators found that certain parts of t he p 13 band of chromosome 11 had been deleted, suggesting that in the genome
of all cells of these individuals a portion of one chromosome 11 was deleted and that this germinal mutation predisposed the children to Wilms ' tumor. Additionally, children with aniridia and a chromosome 11 deletion have a
50% risk of subsequently developing Wilms' tumor, providing still more evidence that germinal loss of genetic
material at chromosome band ll pl3 can predispose individuals to Wilms ' tumor. Subsequently, cytogenetic studies revealed llpl3 deletions in a few tumors from patients
who did not have a germinal chromosome deletion. These
tumor-specific deletions suggested that somatic mutations
at llpl3 were also important in tumorigenesis. In work
done in our laboratory and in others worldwide, this observation has been extended by use of molecular genetic techniques. To date, we have demonstrated that approximately
one-half of a large number of sporadic W ilms' tumors have
detectable genetic changes at llpl3 . From these data it
appeared that one llpl3 gene mutation and a subsequent
mutation or loss of the second 11 p 13 gene are necessary for
tumorigenesis. By extension, we and ot hers hypothesized

We are studying familial
cancers for which only one or a
few gems play a critical role
in tumorigemsis.

neoplasm. Because just one gene may be important for cancer susceptibility, it is feasible to identify, isolate, and characterize it. A knowledge of the identity and function of a
predisposing gene, we reason, will be relevant not only to
the familial form of that cancer but also to the more common, nonfamilial cancer. Furthermore, it is possible that
the gene responsible for a familial predisposition to cancer
likewise may play a role in other cancers seen in the population. On this premise we and other investigators are studying familial cancers for which only one or a few genes are
believed to play a critical role in tumorigenesis. Wilms'
tumor is one such cancer.
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that the inherited mutation in familial Wilms' tumor
occurs at chromosome band 11 p 13.

ilywould have inherited the same llpl3 region from a
common ancestor. The Wilms' tumor phenotype would
cosegregate (i.e., be linked genetically) with llpl3 markers
in the pedigree. However, if affected individuals inherited
different llpl3 regions (no cosegregation), these data
would indicate that the predisposition mutation is not
located there.

RFLP Analysis of a Wilms' Tumor Family
To investigate this hypothesis, we studied a large family
in which six children in three branches had Wilms' tumor.
The clinical features of these patients-early age at diagnosis, bilateral tumors, kidney and tumor histology-were
similar to those ofWilms' tumor patients who had llpl3
deletions and aniridia or genitourinary anomalies. However, this family did not have any of these congenital anomalies, and standard cytogenetic techniques detected no
chromosome aberrations. Using another form of genetic
analysis, we attempted to determine if the predisposition
to Wilms' tumor was genetically linked to DNA markers
that span the llp l3 region. The DNA markers we used
were restriction-fragment length polymorphisms (RFLPs).
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Figure l. Pedigree in which Wilms' tumor (solid symbol) was observed in six children in
the third generation. DNA from lymphoblastoid cell lines or peripheral lymphocytes was
isolated from individuals (underlined identification numbers) and used for RFLP analysis.
Below the underline: B, bilateral tumor; U, unilateral tumor; number, age in months at
diagnosis; squares, males; circles, females; diamonds, child(ren) of unspecified sex. Number below the underline indicates age in months.

Chromosome Band llpl3 Not Linked to Familial
Wilms' Tumor
The pedigree of the Wilms' tumor family studied is
shown in Figure 1. DNA from the individuals whose identification number is underlined in the pedigree was typed
for RFLPs on chromosome 11, especially at llpl3. The
data were analyzed using a maximum likelihood computer
program that calculates the likelihood that genetic markers
segregate with the disease (linkage) versus the likelihood
that the genetic markers segregate randomly with respect to
the disease (lack oflinkage). These likelihoods are expressed
as LOD (log of the odds ratio) scores. By convention, an
LOD score of+ 3.0 or greater is considered statistically significant evidence supporting genetic linkage, whereas an
LOD score of-2. 0 or less is considered sufficient grounds for
rejecting linkage. For the family we studied, linkage analysis
of various llpl3 markers to Wilms' tumor revealed LOD
scores of-5.17 to -2.84. Furthermore, by simple examination of the 11 p 13 marker data, we observed that the affected
children had inherited three different llpl3 regions. Thus,
these data indicated that the familial predisposition to
Wilms' tumor in this pedigree was not due to a mutation
at chromosome band llpl3. By a similar analysis, we also
excluded another region of chromosome 11, 11 p 15, that
has also been indirectly implicated in Wilms' tumor.
Linkage ofWilms' tumor predisposition to llpl3 and
11 p 15 has also been excluded in another large Wilms' tumor
family by other investigators, indicating that the lack
oflinkage to 11 p 13 was not unique to the family we studied.
Lack of linkage of 11 p 13 markers to familial Wilms '
tumor was unexpected in the face of considerable evidence

Researchers commonly employ DNA restriction endonucleases to analyze and manipulate segments of DNA. These
enzymes recognize particular DNA sequences and cleave
the DNA strand at or near t he recognition site. Once the
DNA is cleaved the resultant fragments can be separated
based on size. In general, the size of a restriction fragment
from a particular region of a chromosome is constant.
Occasionally, however, the DNA sequence at the enzyme
recognition site is altered. In this case, the enzyme will not
cleave the DNA strand at that site, and the resulting DNA
fragment will be longer than usual. Alternatively, the
restriction fragment can be lengthened or shortened by
insertions or deletions of DNA. This DNA variability,
which occurs normally throughout the genome and usually
has no known effect on the individual, results in RFLPs.
Because one chromosome with different DNA polymorphisms is inherited from each parent, an individual's set of
RFLPs can be used to discriminate between the chromosome 11 inherited from the father, for example, and that
inherited from the mother. RFLP analysis allows us to trace
in a pedigree a chromosome or a portion of a chromosome
as it is passed from parent to offspring.
If the familial predisposition to Wilms' tumor resulted
from a mutation at llpl3, all affected individuals in a fam-

continued on page 8
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Osteosarcoma continued trom page 3
There generally was no shortage of bone-one donor can
supply substantial amounts and any excess can be easily
stored~but nevertheless the acquisition of bone is governed by the same guidelines as those for the acquisition of
other organs.''

said. "Of the patients that enter a general practitioner's
office, about 57% will have a musculoskeletal complaint,
and often the description can be as vague as 'it hurts here.'
Usually, the only symptom is pain. This is a real problem;
osteosarcoma is detectable only by x-ray, but it's not feasible from a financial standpoint to x-ray everyone who
has a complaint of some type of pain. But if the patient
doesn't respond to the standard management quickly and
significantly, it is critical that he or she undergo x-ray
examination.''
Osteosarcoma is distinctive on radiographs. ''A typical
case," Murray said, "would be a 14- or 15-year-old patient
who has an epiphysis that is almost closed and a large
destructive lesion in the bone just above the epiphysis.
This is often accompanied by the production of new bone.
Benign tumors, however, generally do not interrupt the
cortex of the bone, and the margin between the normal

The potential for infection is greater in pat ients receiving
allografts than in those receiving prostheses, Murray said.
"We were a little concerned that osteosarcoma pat ients
receiving allografts were prone to infection because they
receive heavy chemotherapy; fortunately, our experience
has shown that bones are actually incorporated quite well.
The advantage with allografts is that once the ends of the
bone heal, the bone's function is essentially normal-a biological reconstruction that we don ' t have to worry about. "
The body does not reject allografts as it does other transplants, but Murray said that some patients experience
resorption . ''This may be a rejection phenomenon, but we
don't have any immunological parameters by which we can
predict whether the graft-versus-host relationship is good
or bad."

bone and tumor is very sharp; the tumor may even appear
to show some bone reaction around it. Ninety percent of
osteosarcomas occur at the end of long bones. Of that 90%,
55% will occur at the distal femur, the proximal tibia, or
the proximal fibula."

Allografts, Though Rare, Are an Option

Research Continues
In combination with other modalities, prosthesis

About one in twelve osteosarcoma patients may be eligible for an allograft-the transplant of natural bone-instead
- -ef,tl,resthes~4lefirst,tHegr.1fHeehniquewa~pcrformed 35 years ago,,so it's been around for a long time,"
Murray said. "But its application is limited to tumor that
involves only the middle of the bone.'' M. D. Anderson
once had its own bone bank, but recent federal regulations
have required that all organs now be allocated through
Organ Procurement Organizations (OPOs), Murray said.
The M. D. Anderson bone bank has since been disbanded,
replaced by an OPO that will now handle the dissemination
of bone and other organs to medical facilities in the Gulf
Coast area, he said. ''There was some concern about the
unfair distribution of organs, primarily regarding kidneys,
hearts, and lungs, so the government mandated OPOs.

implantation and allografting will continue to be important componenrs of rhe armamentarium agairrst-osreosar-- - - coma, Murray said. "My colleagues Robert Benjamin,
M.D, and Norman Jaffe, M.D., are continually exploring
new chemotherapy protocols, and the new intraoperative
radiation program ofTyvin Rich, M.D., has added some
new dimensions to the treatment of tumors around the
pelvis. With these modalities and local surgery, we hope
to improve the existing 70% survival rate." ■
Physicians who desire additional information may write John A. Murray,
M.D., Department of General Surgery, Box 106, The University of Texas
M. D. Anderson Cancer Center, 1515 Holcombe Boulevard, Houston,
Texas, 77030, or call (713) 792-7210.
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Bone Marrow continued from page 2
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The trade-offs seem worth
the added time, because drug
dosages can be somewhat
lower for each of the transplantation procedures and the total
dosage higher, according to
Gary Spitzer, M.D., professor
of medicine, deputy director
of the bone marrow transplantation section, and director of
Gary Spitzer
the solid tumor treatment program. The double method, he said, avoids non-bone marrow toxicity in such organs as liver, lung, and heart.
The procedure will be much safer than it is now, Spitzer
said, when the duration of low white-cell and platelet
counts produced by chemotherapy is shorter. "Wider
application is held back by the procedure's toxicity and
potential mortality," he said. " We are constantly researching ways of reducing these. One method may turn out to
be with granulocyte-macrophage colony-stimulating factor, which stimulates recovery of the white blood cells and
makes possible the use of more mature marrow stem cells
from blood in autologous transplantation."
Frank Dunphy, M.D., an
instructor in medicine in the
bone marrow transplantation section, explained drug
combinations used in the program, the usual one being
cyclophosphamide-etoposidecisplatin. Among new ones
being tried, he said, is the
combination of mitoxantrone
Frank Dunphy
and thio-TEPA (triethylenephosphoramide). Since last September, 50 patients have
received the second combination, and in 25% the cancer is
gone, but how durable these patients' remissions turn out
to be remains to be seen, Dunphy said. The physicians are
devising a new system of giving one drug combination
before the first transplantation, the other before the second, to see possible differences in drug effectiveness and
safety.
In the last three years, some 100 patients have been
treated for recurrent breast cancer with high-dose chemotherapy and autologous bone marrow transplantation.
About 60% achieved complete remissions, Spitzer said, and
he estimated that 25% to 35% will be free of disease after
two years or more. " We need longer follow-up to assess
relapse rates," he said. "The experience of conventional
methods of treating breast cancer patients who have
relapsed is that about 10% to 15% of patients are free of disease two to three years later. We have to be sure that the
differences in results of the conventional and high-dose
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therapies are real and not the result of patient selection."
At M. D. Anderson, the overall mortality resulting from
transplantation is 7%, mainly from infectious complications. Spitzer expressed the physicians' hopes for improving the procedure's safety and results and for easing some of
the emotional load. "When the mortality is low and the
patients are mobile and able to exercise," he said, "transplantation will not be so terrifying." ■
Physicians who desire additional information may write Albert B.
Deisseroth , M.D., Department of Hematology, Box 24, The University
ofTexas M. D. Anderson Cancer Center, Houston, Texas, 77030, or call
(713) 792-8750 .
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Genetic Analysis continued from page 5
(as described above) that genetic alterations at llpl3 are
important in the development ofWilms' tumor. Our data,
however, indicate that the predisposing gene in this family
is different from the llpl3 gene. The nature of the interaction, if any, between these two types of genes in the development of tumors in predisposed individuals is unknown.
The predisposing gene may lead to tumorigenesis independently of a gene at llpl3. Alternatively, tumor-specific
genetic alterations at llpl3 may be required in addition
to the predisposing mutation. Analysis of tumors from
familial cases might be informative in this regard. To date,
tumor-specific llpl3 alterations have been observed in
only half of all examined (sporadic) tumors. We previously
thought this was due to our inability to detect subtl~
changes in llpl3 in these tumors. However, in light of
the familial linkage data, it is possible that some sporadic
tumors arise independently of an 11 p 13 mutation and
are a consequence of a mutation at the familial predisposition gene.
A broader question with regard to the llpl3 Wilms'
tumor gene and the familial predisposition gene is their
possible role in the development of cancers other than
Wilms' tumor. Genetic alterations of chromosome 11 have
been observed in some cancers. Whether or not the 11 p 13
Wilms' tumor gene is involved in these cases, either as a

primary or secondary event during tumorigenesis, is still
unclear. Additionally, investigators have noted that a chromosome 11 from a normal cell can suppress the expression
of some transformed characteristics of a tumor cell line.
Though the possible role of the llpl3 Wilms' tumor gene
in tumor suppression is unknown, further work will clarify
the part, if any, the 11 p 13 Wilms' tumor gene plays in cancers other than Wilms' tumor.
For Wilms' tumor, we know that a gene located at chromosome band llpl3 is important in at least some cases.
Now, however, we must also focus our efforts on identifying the gene (or genes) directly linked to the familial predisposition to Wilms' tumor. A knowledge of the nature and
function of both genes will be instrumental in furthering
our understanding of the biology of Wilms' tumor. This
may, in turn, serve as a useful paradigm for understanding
the normal and abnormal functions of multiple genes that
interact in carcinogenesis. ■
Physicians who desire additional information may write Vicki Huff,
Ph.D., or Grady F. Saunders, Ph .D., Ashbel Smith Professor of Biochemistry and Molecular Biology, Department of Biochemistry and
Molecular Biology, Box 117, 1515 Holcombe Boulevard, The University
of Texas M. D . Anderson Cancer Center, Houston, Texas, 77030, or call
(713) 792-2690. Physicians may also write Louise C. Strong, M.D.,
Department of Experimental Pediatrics, Box 209, or call (713) 792-2589.
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